| Literature DB >> 25999941 |
Xianyan Cui1, Jian Wang2, Chaojie Yang2, Beibei Liang2, Qiuxia Ma2, Shengjie Yi2, Hao Li2, Hongbo Liu2, Peng Li2, Zhihao Wu2, Jing Xie2, Leili Jia2, Rongzhang Hao2, Ligui Wang2, Yuejin Hua3, Shaofu Qiu2, Hongbin Song2.
Abstract
Shigella flexneri serotype 2 variant (II:3,4,7,8) was isolated in 2008 and first reported in China in 2013. In the present study, epidemiological surveillance from 2003 to 2013 in China suggested that this serotype first appeared in Guangxi in 2003; it then emerged in Shanghai and Xinjiang in 2004 and in Henan in 2008. Of the 1813 S. flexneri isolates, 58 S. flexneri serotype 2 variant strains were identified. Serotype 2 variant has emerged as a prominent serotype in recent years, with 2a (32.6%), X variant (25.2%), 1a (9.4%), X (6.3%), 2b (5.4%), and 1b (3.6%). According to phenotypic and genotypic analysis, the serotype 2 variant originated from 2a to 2b. A higher antibiotic resistance rate was observed between 2009 and 2013 than that between 2003 and 2008. Among 22 cephalosporin-resistant isolates, bla TEM-1, bla OXA-1, bla CTX-3, bla CTX-14, and bla CTX-79 were detected. Among 22 fluoroquinolone-resistant isolates, a Ser80Ile mutation in parC was present in all of the isolates. Moreover, 21 isolates had three gyrA point mutations (Ser83Leu, His211Tyr, Asp87Asn, or Gly) and one isolate had two gyrA point mutations (Ser83Leu and His211Tyr). The prevalence of His211Tyr in the fluoroquinolone-resistant isolates is concerning, and the mutation was first reported in China. Besides, 22 isolates harbored the aac(6')-Ib-cr gene, and two isolates harbored qnrS1. In view of the increased epidemic frequency and multidrug-resistant strain emergence, continuous surveillance will be needed to understand the actual disease burden and provide guidance for shigellosis.Entities:
Keywords: Shigella flexneri; antibiotic resistance rate; epidemic frequency; multidrug-resistant; serotype 2 variant
Year: 2015 PMID: 25999941 PMCID: PMC4423435 DOI: 10.3389/fmicb.2015.00435
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers for the antibiotic-resistant determinants and integrons.
| F: GGTTAAAAAATCACTGCGTC | 873 | Matar et al., | |
| R: TTACAAACCGTCGGTGACGA | |||
| F: AGAGTGCAACGGATGATG | 868 | Matar et al., | |
| R: CCAGTTACAGCCCTTCGG | |||
| F: ACCGAGCCSACGCTCAA | 221 | This study | |
| R: CCGCTGCCGGTTTTATC | |||
| F: ATGAGTATTCAACATTTCCG | 1080 | Tariq et al., | |
| R: CCAATGCTTAATCAGTGAGG | |||
| F: ATTAAGCCCTTTACCAAACCA | 890 | Ahmed et al., | |
| R: AAGGGTTGGGCGATTTTGCCA | |||
| F: AGTGGTGAGTATCCGACAG | 509 | Galani et al., | |
| R: ATGAAAGTGCGTGGAGAC | |||
| F: GTCTGGCAGCACACTTCCTA | 515 | This study | |
| R: TAGTGCTCAGTGTCGGCATC | |||
| IntI1 | F: ACATGTGATGGCGACGCACGA | 569 | Pan et al., |
| R: ATTTCTGTCCTGGCTGGCGA | |||
| Class 1 integron variable region | hep58: TCATGGCTTGTTATGACTGT | Variable | This study |
| hep59:GTAGGGCTTATTATGCACGC | |||
| Class 1 integron variable region | hep58: TCATGGCTTGTTATGACTGT | Variable | This study |
| aadA1:TGTCAGCAAGATAGCCAGAT | |||
| Class 1 integron variable region | hep58: TCATGGCTTGTTATGACTGT | Variable | This study |
| aadA2: TGATCTCGCCTTTCACAAA | |||
| Class 1 integron variable region | hep58: TCATGGCTTGTTATGACTGT | Variable | This study |
| aadA5: CATCTAACGCATAGTTGAGC | |||
| Class 1 integron variable region | hep58: TCATGGCTTGTTATGACTGT | Variable | This study |
| cmlA1: CAACGATTGGGATTTGACGTACTTT | |||
| IntI2 | F: CACGGATATGCGACAAAAAGGT | 789 | Pan et al., |
| R: GTAGCAAACGAGTGACGAAATG | |||
| Class 2 integron variable region | hep74: CGGGATCCCGGACGGCATGCACGATTTGTA | Variable | Ahmed et al., |
| hep51: GATGCCATCGCAAGTACGAG | |||
| F: TACACCGGTCAACATTGAGG | 648 | Hu et al., | |
| R: TTAATGATTGCCGCCGTCGG | |||
| F: TGAAATGACCCGCCGTAAAGG | 309 | Hu et al., | |
| R: GCTGTGATAACGCAGTTTGTCCGGG | |||
| F: GTACGTGATCATGGACCGTG | 531 | Hu et al., | |
| R: TTCGGCTGGTCGATTAATGC | |||
| F: ATGCGTGCGGCTAAAAAAGTG | 290 | Hu et al., | |
| R: TCGTCGCTGTCAGGATCGATAC | |||
| F: ATTTCTCACGCCAGGATTTG | 516 | Robicsek et al., | |
| R: GATCGGCAAAGGTYAGGTCA | |||
| F: GATCGTGAAAGCCAGAAAGG | 469 | Robicsek et al., | |
| R: ACGAYGCCTGGTAGTTGTCC | |||
| F: CGAGATCAATTTACGGGGAATA | 656 | Tariq et al., | |
| R: AACAAGCTGAAGCGCCTG | |||
| F: ACGACATTCGTCAACTGCAA | 417 | Robicsek et al., | |
| R: TAAATTGGCACCCTGTAGGC | |||
| F: GCAACGCAAAAACAAAGTTAGG | 560 | Pu et al., | |
| R: GTGTTTGAACCATGTACA | |||
Figure 1.
Figure 2.
Comparison and antimicrobial susceptibility to 21 antibiotics among .
| Ceftazidime | 0 | 0 | 0 | 0 | 0 |
| Ceftriaxone | 20 (34.5%) | 12 (35.3%) | 4 (33.3%) | 4 (50%) | 0 |
| Piperacillin | 14 (24.1%) | 10 (29.4%) | 2 (16.7%) | 2 (25%) | 0 |
| Tetracycline | 55 (94.8%) | 31 (91.2%) | 12 (100%) | 8 (100%) | 4 (100%) |
| Cefoperazone | 17 (29.3%) | 9 (26.5%) | 4 (33.3%) | 4 (50%) | 0 |
| Cefazolin | 22 (37.9%) | 14 (41.2%) | 4 (33.3%) | 4 (50%) | 0 |
| Ticarcillin | 56 (96.6%) | 33 (97.1%) | 12 (100%) | 7 (87.5%) | 4 (100%) |
| Ticarcillin/clavulanic acid | 3 (5.2%) | 2 (5.9%) | 0 | 1 (3.6%) | 0 |
| Aztreonam | 2 (3.4%) | 0 | 1 (8.3%) | 1 (3.6%) | 0 |
| Ampicillin | 57 (98.3%) | 33 (97.1%) | 12 (100%) | 8 (100%) | 4 (100%) |
| Chloramphenicol | 54 (93.1%) | 31 (91.2%) | 12 (100%) | 7 (87.5%) | 4 (100%) |
| Trimethoprim/sulfamethoxazole | 25 (43.1%) | 16 (47.1%) | 4 (33.3%) | 3 (37.5%) | 2 (50%) |
| Levofloxacin | 1 (1.7%) | 0 | 0 | 1 (12.5%) | 0 |
| Cefepime | 0 | 0 | 0 | 0 | 0 |
| Imipenem | 0 | 0 | 0 | 0 | 0 |
| nitrofurantoin | 2 (3.4%) | 2 (5.9%) | 0 | 0 | 0 |
| Cefoxitin | 3 (5.2%) | 3 (8.8%) | 0 | 0 | 0 |
| Tobramycin | 7 (12.1%) | 5 (14.7%) | 2 (16.7%) | 0 | 0 |
| Gentamicin | 5 (8.6%) | 4 (11.2%) | 1 (8.3%) | 0 | 0 |
| Norfloxacin | 22 (37.9%) | 16 (47.1%) | 3 (25%) | 3 (37.5%) | 0 |
| Amikacin | 0 | 0 | 0 | 0 | 0 |
Dominant antimicrobial resistance profiles of 58 .
| TE/SXT | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| TE/TIC/AMP/C | 14 (24.1%) | 2 (25%) | 6 (17.6%) | 4 (33.3%) | 2 (50%) |
| TIC/AMP/C/NOR | 2 (3.4%) | 0 | 2 (5.9%) | 0 | 0 |
| TE/TIC/AMP/C/SXT | 8 (13.8%) | 1 (12.5%) | 2 (5.9%) | 3 (25%) | 2 (50%) |
| TE/TIC/AMP/C/NOR | 3 (5.2%) | 1 (12.5%) | 2 (5.9%) | 0 | 0 |
| TIC/AMP/C/SXT/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| TE/GEN/TIC/AMP/C/SXT | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| TE/TIC/AMP/C/SXT/NOR | 5 (8.6%) | 0 | 5 (14.7%) | 0 | 0 |
| CRO/TE/CFZ/TIC/AMP/C | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/TE/CFP/CFZ/AMP/SXT | 1 (1.7%) | 1 (12.5%) | 0 | 0 | 0 |
| CRO/CFP/CFZ/TIC/TE/AMP/C | 2 (3.4%) | 0 | 0 | 2 (16.7%) | 0 |
| CRO/TE/CFZ/TIC/AMP/C/SXT | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| TE/TIC/AMP/C/TO/GEN/SXT/NOR | 1 (1.7%) | 0 | 0 | 1 (8.3%) | 0 |
| CRO/PIP/TE/CFP/CFZ/TIC/AMP/C | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR | 1 (1.7%) | 1 (12.5%) | 0 | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ//TOTIC/AMP/C/NOR | 1 (1.7%) | 0 | 0 | 1 (8.3%) | 0 |
| CRO/PIP/TE/CFZ/TO/TIC/TIM/AMP/C/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/SXT | 1 (1.7%) | 1 (12.5%) | 0 | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR | 2 (3.4%) | 1 (12.5%) | 0 | 1 (8.3%) | 0 |
| CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR | 2 (3.4%) | 0 | 2 (5.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR | 2 (3.4%) | 0 | 2 (5.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
| CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR | 1 (1.7%) | 0 | 1 (2.9%) | 0 | 0 |
Resistance to quinolones or cephalosporin of 58 .
| Non | 21 (53.8) | 3 (15.8) | 9 (42.9) | 1 (7.7) | 6 (66.7) | 1 (33.3) | 4 (100) | 0 | 2 (40) | 1 (33.3) | ≤0.01 |
| Cephalosporin | 13 (33.3) | 9 (47.4) | 8 (38.1) | 6 (46.2) | 3 (33.3) | 1 (33.3) | 0 | 0 | 2 (40) | 2 (66.7) | 0.3 |
| Quinolones | 7 (17.9) | 15 (78.9) | 4 (19) | 12 (92.3) | 3 (33.3) | 2 | 0 | 0 | 2 (40) | 1 (33.3) | ≤0.01 |
| Both | 2 (5.1) | 8 (42.1) | 0 | 7 (53.8) | 3 (33.3) | 1 (33.3) | 0 | 0 | 1 (20) | 1 (33.3) | ≤0.01 |
Figure 3Pulsed-field gel electrophoresis dendrogram and the antibiotic resistance profile of . The original number, origin, serotype, and isolation year are indicated for each strain.
Antibiogram and molecular analysis of the antibiotic-resistance determinants and integrons of .
| 2004607 | CRO/TE/CFP/CFZ/AMP/SXT | |
| SH05Sh584 | CRO/TE/CFZ/TIC/AMP/C/SXT | |
| HN08166 | CRO/TE/CFP/CFZ/TIC/AMP/C | |
| HN08175 | CRO/TE/CFP/CFZ/TIC/AMP/C | |
| SH05Sh582 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C | |
| SH05Sh10 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C | |
| SH05Sh9 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT | |
| SH05sh375 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT | |
| SH05Sh39 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT | |
| SH09sh2-2 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR | |
| SH12Sh104 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR | |
| 2006040 | CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR | |
| SH05sh48 | CRO/PIP/TE/CFZ/TO/TIC/TIM/AMP/C | |
| 2012262 | CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR | |
| HN08096 | CRO/PIP/TE/CFP/CFZ/TO/TIC/AMP/C/NOR | |
| SH13Sh70 | CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR | |
| SH12Sh111 | CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR | |
| 2011154 | CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/SXT | |
| HN12152 | CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/NOR | |
| SH05sh394 | CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C | |
| SH13Sh32 | NIT/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR | |
| SH12Sh160 | CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR | |
Antibiogram and molecular analysis of the antibiotic-resistance determinants and integrons of .
| SH07Sh007 | TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH08Sh265 | TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| 2006095 | TE/TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh282 | TE/TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH09sh188-2 | TE/TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh219 | TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH05sh577 | TE/TIC/AMP/C/SXT/NOR | + | + | Ile | Leu | Gly | Tyr |
| SH11sh473 | TE/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh119 | TE/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH13Sh40 | TE/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH05sh585 | TE/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| HN09103 | TE/TO/GEN/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Asp | Tyr |
| SH09sh2-2 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh104 | CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| 2006040 | CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR | + | – | Ile | Leu | Asn | Tyr |
| SH13Sh70 | CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| HN08096 | CRO/PIP/TE/CFP/CFZ/TO/TIC/AMP/C/NOR | + | – | Ile | Leu | Asn | Tyr |
| HN12152 | CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| 2012262 | CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh111 | CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR | + | + | Ile | Leu | Gly | Tyr |
| SH13Sh32 | NIT/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |
| SH12Sh160 | CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR | + | – | Ile | Leu | Gly | Tyr |